8-K: Precigen Faces Nasdaq Delisting Threat After Share Price Falls Below $1

Precigen, Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1, putting the company at risk of delisting.

Summary

• Precigen, Inc. received a notification from Nasdaq on November 1, 2024, stating that the company is not compliant with the Nasdaq Listing Rule 5450(a)(1) because its share price has been below $1 for 30 consecutive business days.
• The company has until April 30, 2025, to regain compliance by having its stock price close at or above $1 for at least ten consecutive business days.
• If Precigen fails to meet this deadline, it may be eligible for an additional 180-day compliance period by transferring its listing to the Nasdaq Capital Market, provided it meets other listing requirements.
• To maintain the listing on the Nasdaq Capital Market, the company may need to perform a reverse stock split.
• If the company does not regain compliance or is not eligible for an extension, Nasdaq will issue a delisting notification, which the company can appeal.
• Precigen intends to monitor its stock price and consider options, including a reverse stock split, to regain compliance, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (delisting notice) and uncertainty about the company's ability to regain compliance, leading to a low sentiment score.

Negatives

• Precigen's stock price has fallen below the minimum $1 threshold required by Nasdaq.
• The company is at risk of being delisted from the Nasdaq Global Select Market.
• There is no guarantee that the company will be able to regain compliance with the listing rules.

Risks

• The company faces the risk of delisting from the Nasdaq Global Select Market if it cannot raise its stock price above $1.
• A reverse stock split, while a potential solution, could negatively impact shareholder value.
• Failure to regain compliance could lead to a loss of investor confidence and further decline in stock price.

Future Outlook

The company intends to actively monitor its stock price and consider available options to resolve the deficiency and regain compliance with the Bid Price Rule, which could include seeking to effect a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule.

Management Comments

• The company intends to actively monitor the closing bid price of its common stock.
• The company will consider available options to resolve the deficiency and regain compliance with the Bid Price Rule, which could include seeking to effect a reverse stock split.

Industry Context

This announcement is not uncommon in the biotech industry, where companies can experience significant stock price volatility. Delisting notices are a concern for any publicly traded company, and Precigen will need to take decisive action to regain compliance.

Comparison to Industry Standards

• Many biotech companies face similar challenges with maintaining share price compliance, especially during periods of clinical trial uncertainty or market downturns.
• Companies like Sorrento Therapeutics and Cassava Sciences have also faced delisting threats, highlighting the volatility in the sector.
• A reverse stock split is a common strategy used by companies in this situation, but it does not always guarantee long-term compliance or improved investor sentiment.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty about the company's future.
• Creditors may become more cautious about lending to the company.

Next Steps

• Precigen will monitor its stock price.
• Precigen will consider options to regain compliance, including a potential reverse stock split.
• Precigen may need to transfer its listing to the Nasdaq Capital Market if it cannot regain compliance by April 30, 2025.

Key Dates

Keywords

delisting, Nasdaq, compliance, stock price, reverse stock split, listing rule, bid price